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Abstract
Purpose Radiolabelled somatostatin-based antagonists show
a higher uptake in tumour-bearing mouse models than
agonists of similar or even distinctly higher receptor affinity.
Very similar results were obtained with another family of G
protein-coupled receptor ligands, the bombesin family. We
describe a new conjugate, RM2, with the chelator DOTA
coupled to D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 via
the cationic spacer 4-amino-1-carboxymethyl-piperidine for
labelling with radiometals such as 111In and 68Ga.
Methods RM2 was synthesized on a solid support and
evaluated in vitro in PC-3 cells. IC50 and Kd values were
determined. The antagonist potency was evaluated by
immunofluorescence-based internalization and Ca2+ mo-
bilization assays. Biodistribution studies were performed
in PC-3 and LNCaP tumour-bearing mice with 111In-RM2
and 68Ga-RM2, respectively. PET/CT studies were per-
formed on PC-3 and LNCaP tumour-bearing nude mice
with 68Ga-RM2.
Results RM2 and 111In-RM2 are high-affinity and selec-
tive ligands for the GRP receptor (7.7±3.3 nmol/l for
RM2; 9.3±3.3 nmol/l for natIn-RM2). The potent antagonistic
properties were confirmed by an immunofluorescence-based
internalization and Ca2+ mobilization assays. 68Ga- and
111In-RM2 showed high and specific uptake in both the
tumour and the pancreas. Uptake in the tumour remained
high (15.2±4.8%IA/g at 1 h; 11.7±2.4%IA/g at 4 h), whereas
a relatively fast washout from the pancreas and the other
abdominal organs was observed. Uptake in the pancreas
decreased rapidly from 22.6±4.7%IA/g at 1 h to 1.5±0.5%
IA/g at 4 h.
Conclusion RM2 was shown to be a potent GRPr antagonist.
Pharmacokinetics and imaging studies indicate that 111In-RM2
and 68Ga-RM2 are ideal candidates for clinical SPECT and
PET studies.
Keywords Prostate cancer . Gastrin-releasing peptide
receptor . Bombesin . Gallium-68 . Indium-111
Introduction
Radiolabelled peptides have attracted considerable interest
because of their wide applicability in the development of
target-specific radiopharmaceuticals [1, 2]. Somatostatin
receptor targeting is an established method to image and
treat somatostatin receptor-positive tumours [3]. Generally,
the good internalization properties of agonists have been
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considered crucial for an efficient accumulation of a
radioligand in cells to give optimal tumour visualization
in vivo [4, 5]. We have recently shown for somatostatin
receptors 2 and 3, that antagonists have a higher tumour
uptake than the corresponding agonists despite a very low
internalization rate [6]. Among the different regulatory
peptides explored for tumour targeting, bombesin and
bombesin derivatives have attracted significant interest as
they exhibit high affinity for the gastrin-releasing peptide
receptor (GRPr), which is highly expressed on major
human tumours such as prostate [7, 8], breast [9, 10] and
gastrointestinal stromal tumours [11] and small-cell lung
cancer (SCLC) [12]. Several radiolabelled bombesin ana-
logues have been developed and their clinical and preclin-
ical applications in targeting GRPr-positive tumours have
been reported [13–16]. Bombesin elicits a broad spectrum
of biological activities and may be involved as an autocrine
growth factor in the pathophysiology of SCLC and other
cancer types [17].
Due to the mitogenic properties of bombesin agonists,
there has been considerable interest in the design of
metabolically stable and selective GRPr antagonists and in
the development of radiolabelled peptides for imaging (PET,
SPECT) and targeted radionuclide therapy. Several classes of
bombesin antagonists have been explored by the modification
of the C-terminal residues of naturally amidated bombesin
agonists [18, 19]. Cescato et al. [20] demonstrated the
superiority of 99mTc-demobesin1 as a tumour-targeting agent
with respect to a comparably potent radioagonist. Further,
Abd-Elgaliel et al. [21] developed the 111In-DOTA-amino-
hexanoyl-[D-Phe6, Leu-NHCH2CH2CH2CH3
13, des-Met14]-
BBN(6-14) conjugate, supporting the use of radiolabelled
bombesin antagonists as potential candidates for in vivo
imaging of GRPr-positive tumours. Very recently, we
reported a direct comparison of a potent radiolabelled
statin-based antagonist 111In-RM1 and the potent agonist
111In-AMBA [22]. Despite the lower GRPr affinity, the
radioantagonist showed higher tumour uptake and superior
pharmacokinetics than the radioagonist.
We describe here the synthesis and the pharmacological
evaluation of a new DOTA-conjugated bombesin antagonist,
RM2 (DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-
Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2), supporting our hy-
pothesis of the superiority of G protein-coupled receptor
antagonists over agonists in vivo. We have shown earlier that
positive charges at the N-terminal of bombesin-based
agonists (BN(7-14)) lead to improved bombesin receptor
affinities (Zhang H.; PhD thesis, University of Basel, 2006.
http://edoc.unibas.ch/586). We were interested to determine
if a similar effect could also be seen when employing
antagonists. Therefore we linked DOTA (1,4,7,10-tetraaza-
cyclododecane-1,4,7,10-tetraacetic acid) [23] via a positively
charged spacer (4-amino-1-carboxymethyl-piperidine) to the
potent antagonist JMV594 [24] and evaluated the use of the
111In-labelled conjugate for SPECT and the 68Ga-labelled
peptide for PET. The antagonistic properties of the conjugate
were evaluated in vitro using an immunofluorescence-based
internalization assay and inhibition of Ca2+ mobilization
assay using agonists. We were interested to determine if
there is a difference between the use of an androgen-
dependent and an androgen-independent tumour xenograft.
Therefore its pharmacokinetics were studied in PC-3 and
LNCaP tumour-bearing nude mice using SPECT/CT and
PET/CT.
Materials and methods
Chemicals
All chemicals were obtained from commercial sources
and used without additional purification. Rink amide 4-
methyl-benzhydrylalanine (MBHA) resin and all the
Fmoc-protected amino acids are commercially available
from NovaBiochem (Laeufelfingen, Switzerland), DOTA
(tBu)3 from Chematec (Dijon, France), Fmoc-4-amino-1-
carboxymethyl-piperidine from NeoMPS (Strasbourg,
France) and 111InCl3 from Covidien Medical (Petten, The
Netherlands). BIM26226 [25] was provided by Ipsen
Biotech (Paris, France). Electrospray ionization mass spec-
troscopy (ESI-MS) was carried out with a Finnigan SSQ
7000 spectrometer (Bremen, Germany). Analytical high-
performance liquid chromatography (RP-HPLC) was per-
formed on a Hewlett Packard 1050 HPLC system with a
multiwavelength detector and a flow-through Berthold LB
506 Cl γ-detector using a Macherey-Nagel Nucleosil 120
C18 column (Oensingen, Switzerland) (eluent A comprising
0.1% TFA in water, eluent B comprising acetonitrile;
gradient 0–30 min, 95% to 55% A; flow 0.750 ml/min).
Semipreparative RP-HPLC was performed on a Metrohm
HPLC system LC-CaDI 22-14 (Herisau, Switzerland) with a
Macherey-Nagel VP 250/21 Nucleosil 100-5 C18 column
(eluent A comprising 0.1% TFA in water, eluent B
comprising acetonitrile; gradient: 0–20 min, 95% to 30%
A; flow 15 ml/min). Quantitative gamma counting was
performed on a COBRA 5003 γ-system well counter from
Packard Instruments.
Human embryonic kidney 293 (HEK293) cells, stably
expressing the HA epitope-tagged human GRPr (HEK-
GRPr), were generated as previously described [20] and
cultured at 37°C in an atmosphere containing 5% CO2 in
DMEM with GlutaMAX-I containing 10% (v/v) fetal
bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml
streptomycin and 750 μg/ml G418. Human prostate cancer
cells (PC-3) were obtained from ATCC (Manassas, VA),
cultured in DMEM or in Ham’s F-12 K medium,
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supplemented with vitamins, amino acids, penicillin/strep-
tomycin and 10% FBS in a humidified atmosphere
containing 5% CO2 at 37°C. LNCaP cells were cultured
in RPMI 1640 medium supplemented with 1nM of
synthetic androgen R1881 (NEN), amino acids, penicillin/
streptomycin, sodium pyruvate and 10% FBS in a humid-
ified atmosphere containing 5% CO2 at 37°C. All culture
reagents were from Invitrogen (Basel, Switzerland) or from
BioConcept (Allschwil, Switzerland).
Synthesis of peptide conjugate and metallation
The peptide–chelator conjugate RM2 was synthesized
manually according to standard Fmoc chemistry [26] using
Rink amide MBHA resin. The spacer and the prochelator
DOTA(tBu)3 were consecutively coupled to the peptide
with HATU as activating agent. The peptide conjugate was
purified according to the method of Heppeler et al. [23].
The peptide was purified by RP-HPLC and characterized
by ESI-MS. The conjugate was complexed with natInCl3
using a previously described procedure [14]. The pure
product (yields ranging from 70% to 80%) after lyophi-
lization was analysed by analytical RP-HPLC and charac-
terized by ESI-MS.
Radiolabelling
111In-RM2 was prepared by dissolving 10 μg of peptide in
250 μl of sodium acetate buffer (0.4 mol/l, pH 5.0) and
incubating with 111InCl3 (110–220 MBq) for 30 min at 95°C.
To obtain structurally characterized homogeneous ligands, 1
equivalent of natInCl3·5H2O was added and the final solution
incubated again at 95°C for 30 min. For biodistribution
studies the labelling was performed following the same
procedure but without the addition of the In3+ salt.
The 68GaCl3 was provided by Charité CVZ Zentrales
Radionuklid Labor (Berlin, Germany). HEPES solution
(350 μl, 0.25 M) was added to an aqueous solution of RM2
(20 μL/20 μg) in a Wheaton vial. 68GaCl3 solution (400 μl,
200–240 MBq; 97.6% acetone/ 0.05 M HCl) was added and
the pH adjusted to 3.6–3.9. The solution was heated in a
microwave at 75 W (95°C) for four times for 30 s each time
and with 30 s between each heating. The reaction mixture
was diluted with 5 ml of water and purified through a SepPak
C18 cartridge preconditioned as described previously [27].
The product was eluted with EtOH (500 μl) and the
radiochemical purity was checked by HPLC and instant
thin-layer chromatography.
Receptor binding affinity and selectivity
IC50 values of RM2 and
natIn-RM2 were determined by in
vitro GRPr autoradiography on cryostat sections of well-
characterized prostate carcinomas as described previously
[7, 28]. The radioligand used was [125I-Tyr4]-bombesin,
known to preferentially bind to the GRPr [29], and [125I-D-
Tyr6, β-Ala11, Phe13, Nle14]BN(6-14) as universal bomb-
esin receptor ligand. The binding affinity profile for the
three bombesin receptor subtypes was determined as
described in detail previously [30].
The cellular binding saturation experiments were per-
formed using increasing concentrations of the 111/natIn-DOTA
peptide ranging from 0.1 to 1000 nmol/l. Confluent PC-3
cells were seeded into six-well plates (about 1.0×106 cells)
24 h before starting the experiments. For blocking experi-
ments, 1 mmol/l of BIM26226 ([D-F5Phe
6,Ala11]BN(6-13)
OMe) [25] was used. For each radioligand, triplicates were
prepared for every concentration, for both total binding and
nonspecific binding. Before adding the radioligands to the
wells, the plates were placed on ice for 30 min. After adding
the radioligands and BIM26226 for nonspecific binding, the
plates were incubated for 2 h at 4°C. The binding buffer was
then aspirated and the cells were washed twice with ice-cold
phosphate-buffered saline (pH 7.4); this represented the free
fraction. Finally, the cells were collected with 1 N NaOH;
this corresponded to the bound fraction. Specific binding was
calculated by subtracting nonspecific from total binding at
each concentration of radioligand. Affinity (Kd) and binding
site density (Bmax) were calculated from Scatchard plots
using Origin 7.5 software (Microcal Software, Northampton,
MA).
Internalization
For internalization experiments, approximately 3 kBq of
111/natIn-labelled peptide (0.25 pmol) was added to the
medium and the cells were incubated (in triplicate) for 0.5,
1, 2 and 4 h at 37°C in an atmosphere containing 5% CO2.
A large excess of BIM26226 was used (2 μmol/l, 100 μl) to
determine nonspecific internalization. At each time point
the cells were treated as recently described [14].
Immunofluorescence microscopy
Immunofluorescence microscopy-based internalization
assays with HEK-GRPr cells were performed as previously
described [20]. HEK-GRPr cells were treated with either
10 nmol/l bombesin or 1 μmol/l RM2 or, to evaluate
potential antagonism, with 10 nmol/l bombesin in the
presence of a 100-fold excess of RM2 for 30 min at 37°C in
an atmosphere containing 5% CO2 in growth medium, and
then processed for immunofluorescence microscopy using
first mouse monoclonal HA-epitope antibody (Covance,
Berkeley, CA) at a dilution of 1:1000 and second Alexa
Fluor 488 goat anti-mouse IgG (H + L, Molecular Probes,
Eugene, OR) at a dilution of 1:600. The cells were imaged
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using a Leica DM RB immunofluorescence microscope and
an Olympus DP10 camera.
Ca2+ mobilization assay
Intracellular Ca2+ mobilization was measured in PC-3 cells
using a Fluo-4NW calcium assay kit (Molecular Probes,
Eugene, OR) as described previously [20]. In brief, PC-3 cells
were seeded (10,000 cells per well) into 96-well plates and
cultured for 2 days at 37°C in an atmosphere containing 5%
CO2. On the day of the experiment, the cells were washed
with assay buffer (1 × HBSS, 20 mmol/l HEPES) containing
2.5 mmol/l probenecid. The cells were then incubated with
100 μl/well Fluo-4NW dye in assay buffer for 30 min at 37°C
in an atmosphere containing 5% CO2 and then for a further
30 min at room temperature. The dye-loaded cells were
transferred to a SpectraMax M2e (Molecular Devices,
Sunnyvale, CA) and intracellular Ca2+ mobilization was
recorded in a kinetic experiment for 60 s at room temperature
monitoring fluorescence emission at 520 nm (λex=485 nm) in
the presence of the compounds to be tested. Data are shown
as percentage of the maximum calcium response obtained
with ionomycin as reported previously [20].
Biodistribution experiments
All animal experiments were performed in compliance with the
Swiss (no. 798) and German regulations for animal treatment.
The pharmacokinetics of 111In-RM2 were evaluated in
female nude mice (3 weeks old), implanted subcutaneously
with 10 million PC-3 tumour cells, freshly expanded in a
sterilized solution of phosphate-buffered saline (pH 7.4).
The mice (20–22 g) were injected into the tail vein 11 days
after inoculation with 10 pmol of radiolabelled peptides
(about 0.18 MBq, 100 μl). For the determination of
nonspecific uptake in tumour or receptor-positive organs,
a group of four animals were preinjected (5 min) with
0.02 μmol of unlabelled peptide. At 1, 4, 24, 48 and 72 h
the mice (in groups of 4 to 11) were killed and organs of
interest were collected, rinsed, blotted, weighed and
counted in a γ-counter. The percentage of injected activity
per gram (%IA/g) was calculated for each tissue.
The biodistribution experiments with 68Ga-RM2 were
performed using male nude mice (NMRI nu/nu, Taconic) at
3–4 weeks of age. The animals were implanted subcutane-
ously with PC-3 (2×106 cells/mouse) or LNCaP cells
(1×107 cells/mouse) in the right shoulder. Mice to be
injected with LNCaP cells were pretreated with testosterone
pellets (12.5 mg, 90 days release; IRA, Sarasota, FL)
implanted 3–4 days before tumour cell inoculation. For the
tumour cell implantation, cells were suspended in Matrigel
(BD Biosciences) to a final volume of 100 μl. The animals
(30–35 g) were injected intravenously 4 weeks after
implantation with 80 pmol of 68Ga-RM2 (100 μl, 150–
240 kBq). The animals were killed at different times from
20 to 120 min after injection (three mice for each time
point). In addition, a group of three mice were preinjected
with 0.06 μmol of RM2 and killed at 1 h later to determine
nonspecific uptake.
Imaging
SPECT/CT was performed with a four-head multiplexing
multipinhole camera (NanoSPECT/CT; Bioscan). Each
head was equipped with a tungsten-based collimator of
nine 1.4-mm diameter pinholes. The apertures used in this
study provided a reconstructed resolution in the submilli-
metre range at 140 keV [31]. Two PC-3 tumour-bearing
nude mice were anaesthetized with 4% isoflurane/oxygen
24 h after intravenous injection of 42 MBq of 111In-RM2.
The acquisition mode was helical for both modalities and
the time per view for the SPECT scans was 30 s. The
acquisition time was approximately 15 min for the SPECT
scan. CT scans were performed with an integrated CT
scanner using a tube voltage of 45 kV and an exposure time
of 1,500 ms per view. After acquisition, the SPECT data
were reconstructed iteratively with HiSPECT software
(Scivis). The CT data were reconstructed using a cone-
beam filtered back-projection. The SPECT and CT data
were automatically coregistered as both modalities shared
the same axis of rotation. The fused datasets were analysed
in InVivoScope postprocessing software (Bioscan).
The PET/CTstudies were performed using a multimodality
Inveon PET/CT camera (Siemens). Approximately 50 min
after intravenous injection of about 7 MBq 68Ga-RM2 (400
pmol) PC-3 and LNCaP tumour-bearing mice were anaes-
thetized with 4% isoflurane/oxygen. At a constant low
breathing frequency (about 60 min-1) animals were trans-
ferred to the camera bed and fixed for static PET imaging
with a duration of 30 min followed by CT. Breathing
frequency and body temperature of the animals were
continuously monitored. Images were recorded, recon-
structed and analysed using Inveon-specific acquisition and
research software packages.
Results
RM2 (Fig. 1) was synthesized using solid-phase peptide
synthesis (Fmoc chemistry). The 111In-RM2 conjugate was
obtained in >95% radiolabelling yield at a maximum
specific activity of 30 GBq/μmol. 68Ga-RM2 was obtained
with a specific activity of 10 GBq/μmol. The metallated
and unmetallated conjugates were purified by RP-HPLC
and characterized by ESI-MS (RM2, 1678.1 [M + K+];
natIn-RM2, 1755.7 [M + H+]).
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Figure 2a shows the cellular uptake of 111In-RM2 in PC-
3 cells. The amount of surface associated activity exceeded
the amount of internalized activity at all time points. At 4 h the
amount of specifically internalized activity was 3.7±0.4%
while 15.9±0.9% was surface-bound. GRPr affinities of
RM2 and natIn-RM2 were determined by a competitive
binding assay using [125I-Tyr4]BN as radioligand (Table 1).
On the human GRPr, the IC50 values were 7.7±3.3 nmol/l for
RM2 and 9.3±3.3 nmol/l for natIn-RM2. The bombesin
receptor subtype binding profile demonstrated excellent
selectivity of RM2 in showing good binding affinity to
GRPr (9.3±0.7 nmol/l) and >103 nmol/l to NMBr and BB3r.
Saturation binding experiments were performed at 4°C
by incubating for 2 h with increasing concentrations of
111/natIn-RM2 (Fig. 2b). The Kd value was 2.9±0.4 nmol/l while
the Bmax value was 1.1±0.05 nmol/l. This Bmax value
corresponding to 5.5×105 binding sites per cell is in agreement
with literature data [32].
The antagonistic properties of RM2 were confirmed by a
immunofluorescence-based internalization assay using
HEK-GRPr cells. Figure 3 shows that 10 nmol/l bombesin
was able to trigger receptor internalization into HEK-GRPr
cells. RM2 was not able to stimulate GRPr internalization
even at a concentration of 1,000 nmol/l. However, at a
concentration of 1,000 nmol/l together with 10 nmol/l of
bombesin, the peptide was able to prevent the bombesin-
induced receptor internalization. The Ca2+ mobilization
assay was performed to determine dose-response curves of
the bombesin antagonist in PC-3 cells. RM2 behaved as an
antagonist shifting the dose-response curve of bombesin to
a higher molar range when present at a concentration of
10 μmol/l together with bombesin. Moreover, tested alone
at 1 μmol/l and 10 μmol/l the peptide had no effect on
intracellular calcium mobilization (Fig. 4).
Biodistribution data from PC-3 tumour-bearing athymic
nude mice are shown in Table 2. 111In-RM2 displayed fast
blood clearance with 0.05±0.04 %IA/g remaining in the
blood at 4 h after injection. The uptake in the organs of the
gastrointestinal tract, which are known to express GRPr,
such as the pancreas, stomach and intestine, was high and
specific, but the radiopeptide was washed out quickly. The
pancreas uptake decreased rapidly from 22.6±4.7%IA/g at
1 h to 1.5±0.5%IA/g at 4 h. High uptake was observed in
the PC-3 tumour with 15.2±4.8%IA/g at 1 h and the uptake
was still high at 4 h with 11.7±2.4%IA/g, and even at later
time points (6.8±1.0 %IA/g at 24 h; 4.7±0.4%IA/g at 48 h;
4.1±0.3%IA/g at 72 h). The long retention in the tumour
indicates that RM2 labelled with 177Lu or 90Y may be a
successful therapeutic agent.
The radiopeptide was quickly washed out from nontarget
tissues leading to very high tumour to normal organ ratios
which increased over time. For instance, tumour to kidney
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peptide chelator conjugate RM2
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Fig. 2 a Internalization (squares) of 111In-RM2 in PC-3 cells is low,
while a higher percentage of the radioconjugate remains bound to cells
(circles). Data are the mean values from three independent experiments
performed in triplicate. b Scatchard plots of 111In-RM2 from saturation-
binding experiments on PC-3 cells. The graphs were produced using
Origin 7.5 software (Microcal Software, Northampton, MA)
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and tumour to blood ratios increased from 3.2 and 19.8 at
1 h to 5.5 and 6,840 at 24 h, respectively. SPECT/CT
images of a PC-3 tumour-bearing mouse 24 h after injection
of 42 MBq 111In-RM2 illustrating the high uptake in the
tumour are shown in Fig. 5.
Uptake in the GRPr rich tissues, as well as in the tumour,
were found to be significantly reduced in the animals
preinjected with an excess of cold peptide, indicating a
specific GRPr-mediated uptake. The pharmacokinetics of
68Ga-RM2 was studied in male nude mice bearing the
androgen-independent PC-3 xenograft reported to show
high GRPr expression (Table 3) or the androgen-dependent
LNCaP xenograft that shows about 40-fold lower GRPr
expression (Table 4) [33]. In PC-3 tumour-bearing mice
10 nM bombesin
10 nM bombesin
+ 1000 nM RM2
no peptide
1000 nM RM2
Immunofluorescence
(HEK-GRPR cells)
Fig. 3 GRP receptor internali-
zation induced by bombesin is
efficiently antagonized by the
bombesin analogue RM2. Top
panels: HEK-GRPr cells were
treated for 30 min with vehicle
(no peptide) or with 10 nM
bombesin, a concentration in-
ducing a submaximal internali-
zation effect. Bottom panels:
HEK-GRPr cells were treated
for 30 min with 1000 nM RM2
alone or with 10 nM bombesin
in the presence of 1000 nM
RM2
Table 1 Comparison of the Kd and IC50 values of RM1 and RM2 and
their natIn-metallated counterparts
RM1 natIn-RM1 RM2 natIn-RM2
IC50 (nM) 35±13 14±3.4 7.7±3.3 9.3±3.3
Kd (nM) 8.5±2.7 2.9±0.4
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Fig. 4 Dose-response curves of the bombesin analogue RM2
determined by the Ca2+ mobilization assay. PC-3 cells were treated
either with bombesin at concentrations ranging between 0.01 nM and
10 μM alone (circles), or with bombesin at the same concentrations
together with 10 μM of the bombesin analogue RM2 (squares). RM2
behaves as an antagonist shifting the dose-response curve of bombesin
to a higher molar range. When tested alone, RM2 at a concentration of
10 μM (triangles) has no effect on calcium mobilization in PC-3 cells
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high accumulation was found in the tumour (9.6±1.4%IA/g
at 20 min). The uptake in the tumour increased with time
reaching a maximum value of 14.7±2.1%IA/g at 80 min,
while decreasing in the GRPr-positive organs (45.9±4.7%
IA/g at 20 min and 22.4±6.6%IA/g at 80 min in the
pancreas). The kidney uptake was comparable to the
tumour uptake at 20 min, but decreased significantly; at
80 min the tumour to kidney ratio was 6. Most likely due to
their lower GRPr expression status [34], LNCaP tumours
showed lower uptake at each time point resulting in
decreased tumour to target tissue ratios. The 68Ga-RM2
was quickly cleared from the nontarget tissue and the
blood. These pharmacokinetic data are reflected in the
microPET/CT images presented in Fig. 6. Maximum
intensity projections in PC-3 and LNCaP mice (unblocked
and blocked with 100 μg RM2 per mouse) show the
Table 2 Biodistribution of 111In-RM2 in female nude mice bearing PC-3 tumours. Values are means±SD %IA/g (n=4)
Organ 1 h 4 h 4 h
blockinga
24 h 48 h 72 h
Blood 0.77±0.28 0.05±0.04 0.13±0.02 0.003±0.00 0.002±0.00 0.001±0.00
Heart 0.32±0.09 0.04±0.03 0.09±0.01 0.02±0.01 0.01±0.00 0.02±0.02
Liver 0.49±0.12 0.18±0.06 0.34±0.03 0.09±0.01 0.07±0.01 0.06±0.02
Spleen 0.53±0.20 0.12±0.06 0.16±0.02 0.06±0.02 0.05±0.01 0.06±0.03
Lung 0.70±0.30 0.10±0.07 0.19±0.01 0.04±0.03 0.11±0.24 0.04±0.02
Kidney 4.78±1.11 2.14±0.73 2.98±0.20 1.25±0.16 0.91±0.09 0.74±0.18
Stomach 3.15±0.78 1.07±0.15 0.12±0.02 0.06±0.02 0.03±0.01 0.05±0.01
Intestine 2.11±0.47 0.25±0.15 0.11±0.01 0.04±0.01 0.03±0.01 0.03±0.01
Adrenal 3.46±2.07 1.17±0.54 1.10±0.60 0.71±0.29 0.54±0.29 0.50±0.34
Pancreas 22.64±4.71 1.55±0.48 0.10±0.00 0.32±0.09 0.19±0.04 0.19±0.02
Pituitary 7.00±5.68 0.59±0.55 0.58±0.49 0.07±0.33 0.21±0.33 0.51±0.24
Muscle 0.29±0.17 0.05±0.04 0.06±0.02 0.02±0.01 0.01±0.01 0.02±0.01
Bone 0.91±0.68 0.35±0.57 0.35±0.11 0.20±0.18 0.12±0.11 0.15±0.05
Tumour 15.23±4.78 11.75±2.43 0.45±0.04 6.84±1.02 4.67±0.39 4.07±0.34
Tumour/blood ratio 19.8 235 2,280 2,335 4,070
Tumour/kidney ratio 3.2 5.5 5.5 5.1 5.5
Tumour/liver ratio 31.0 65.3 76.0 66.7 67.8
Tumour/muscle ratio 52.5 235 342 467 203
a Blocked with 20 nmol of RM2
Fig. 5 SPECT/CT of a PC-3
tumour-bearing nude mouse 24 h
after injection of 42 MBq 111In-
RM2. High specific uptake is
seen in the xenografted tumour in
the left shoulder. Significantly
less activity is seen in the
kidneys. Activity can also be
seen in the bowel and the
bladder. a Maximum intensity
projection SPECT/CT image;
b–d reconstructed slices through
the xenografted tumour
(b: sagittal, c: coronal, d: axial)
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specific tumour targeting and very low background.
Predominant renal excretion was demonstrated by high
kidney uptake and urinary bladder accumulation in
conjunction with low uptake in the small bowel.
Biodistribution and PET imaging indicated the excellent
GRPr targeting mechanism of radiolabelled RM2 inde-
pendent of the androgen responsiveness of the prostate
cancer xenograft model used.
Discussion
The use of radiolabelled peptide antagonists for receptor
targeting of tumours in vivo has attracted attention since the
seminal paper of Ginj et al. [6]. It was shown that compared
with agonists, somatostatin receptor antagonists are superi-
or in terms of targeting more receptor binding sites and
consequently demonstrate higher tumour uptake. Based on
Organ 20min 60min 80min 100min 120min
Blood 1.67±0.51 0.59±0.12 0.51±0.15 0.46±0.09 0.32±0.06
Heart 0.67±0.22 0.27±0.09 0.22±0.09 0.27±0.07 0.20±0.05
Liver 0.87±0.19 0.39±0.03 0.47±0.04 0.30±0.10 0.29±0.07
Spleen 0.99±0.53 0.34±0.05 0.25±0.01 0.17±0.10 0.32±0.09
Lung 1.49±0.07 0.61±0.08 0.59±0.08 0.64±0.33 0.37±0.05
Kidney 9.71±4.66 3.34±0.54 2.41±0.42 1.90±0.38 2.23±0.02
Stomach 3.25±0.31 3.56±0.42 4.21±2.28 2.97±0.65 2.40±0.32
Intestine 2.87±0.81 2.67±1.14 3.77±2.76 1.73±0.10 3.28±1.78
Adrenal 8.46±0.94 1.10±0.60 2.30±1.49 3.76±2.53 2.36±0.26
Pancreas 46.95±4.71 30.74±1.97 22.43±6.65 19.40±0.47 16.00±1.85
Muscle 0.57±0.33 0.12±0.03 0.19±0.13 0.08±0.03 0.14±0.08
Bone 0.62±0.20 0.32±0.08 0.22±0.17 0.33±0.05 0.26±0.06
Tumour 9.59±1.45 14.11±1.88 14.66±2.12 11.33±3.87 13.61±0.64
Urine 36.89±6.62 68.50±6.69 75.16±11.38 75.94±4.93 81.46±10.97
Tumour/blood ratio 5.7 18.1 28.7 24.6 42.5
Tumour/kidney ratio 0.98 4.22 6.1 5.9 6.1
Tumour/liver ratio 11.0 36.2 31.2 37.8 46.9
Tumour/muscle ratio 16.8 117.6 77.1 141.6 97.2
Table 3 Biodistribution of
68Ga-RM2 in male nude mice
bearing PC-3 tumours. Values
are means ±SD %IA/g (n=4;
urine values are %IA)
Organ 20min 60min 80min 100min 120min
Blood 1.73±0.27 0.78±0.19 0.67±0.31 0.45±0.18 0.35±0.08
Heart 0.79±0.14 0.30±0.04 0.26±0.09 0.20±0.03 0.18±0.02
Liver 1.07±0.41 0.60±0.09 0.42±0.11 0.38±0.04 0.34±0.09
Spleen 1.22±0.63 0.49±0.24 0.29±0.06 0.41±0.18 0.33±0.15
Lung 1.57±0.29 0.61±0.01 0.61±0.16 0.49±0.17 0.33±0.07
Kidney 5.68±2.12 2.14±0.07 1.99±0.38 2.02±0.72 1.86±0.53
Stomach 4.23±0.53 3.94±1.12 3.52±0.91 2.58±0.79 4.10±2.66
Intestine 3.90±0.41 2.06±1.14 2.44±0.59 2.21±0.59 2.34±0.38
Adrenal 7.09±1.02 3.19±1.13 5.21±2.67 4.64±1.41 2.99±0.34
Pancreas 60.13±5.26 39.32±4.17 43.85±6.24 29.62±4.33 28.08±3.24
Muscle 0.40±0.04 0.22±0.06 0.17±0.05 0.13±0.02 0.12±0.03
Bone 0.55±0.14 0.29±0.12 0.21±0.06 0.24±0.05 0.19±0.05
Tumour 5.94±1.80 5.50±0.39 6.79±1.35 6.03±1.14 8.18±1.89
Urine 39.85±9.45 61.60±8.54 77.56±14.29 69.82±9.8 81.67±5.51
Tumour/blood 3.4 7.1 10.1 13.4 23.4
Tumour/kidney 1.0 2.6 3.4 3.0 4.4
Tumour/liver 5.5 9.2 16.2 15.9 24.0
Tumour/muscle 14.8 25 39.9 46.4 68.2
Table 4 Biodistribution of
68Ga-RM2 in male nude mice
bearing LNCaP tumours. Values
are means ±SD %IA/g (n=3;
urine values are %IA)
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these results research groups have focused their attention on
the development of new radioantagonists for tumour
targeting [20, 21, 35]. Despite this progress little is known
about structural parameters determining the antagonistic
potential of radiometal-labelled bombesin-based antago-
nists, such as the influence of the metal complex, the spacer
separating the reporting unit from the pharmacophoric
peptide, receptor subtype profile etc. In addition, the origin
of the long residence time in tumours found by us and
others [20, 22] is not yet known.
We report here on the development of a DOTA-
conjugated radiopeptide for the diagnosis and therapy of
bombesin receptor-positive tumours. The DOTA mono-
amide coupled chelator can form complexes with a variety
of trivalent and divalent radiometals to produce radio-
labelled bioconjugates with high in vitro and in vivo
stability [23]. In our previous work, the statin-based
bombesin antagonist was linked via Gly-aminobenzoic acid
to DOTA for a direct comparison with the potent agonist
AMBA [22]. In order to potentially improve the pharma-
cological performance, a statin analogue was coupled to the
positively charged spacer 4-amino-1-carboxymethyl piper-
idine. The Kd and the IC50 values of
natIn-RM2 are indeed
3-fold and 1.5-fold higher, respectively, than those of RM1
[22], indicating that positive charges may be a structural
motif to increase binding affinity (Table 1). Excellent
antagonist properties of RM2 were confirmed by immuno-
fluorescence and Ca2+ mobilization assays. The presence of
a low concentration of RM2 inhibits the receptor internal-
ization triggered by bombesin. In addition, the mobilization
of Ca2+ caused by agonists was efficiently inhibited by
RM2.
The pharmacokinetics of 111In-RM2 were studied in PC-
3 tumour-bearing nude mice. The radioconjugate was taken
up by the tumour and the receptor-positive organs at early
time points but it was washed out at a different rate; the
pancreas uptake decreased by a factor of 14.6 within 4 h
while the tumour uptake decreased by a factor of only 1.3
over the same time period. The uptake was specific and
receptor-mediated; more than 95% of the uptake in the
tumour and in the pancreas was blocked by preinjection of
20 nmol RM2. The fast clearance from the abdominal
organs, including the pancreas, is consistent with the few
reported data of bombesin-based radioantagonists [20–22]
and it differs distinctly from the in vivo behaviour of the
agonists that show high and persistent uptake in the
abdominal organs [14–16, 36]. The reason for the different
pharmacokinetic behaviour is not understood yet. It may be
due to species differences (PC-3 is of human origin), or
may result from a more efficient perfusion in the pancreas
and intestine. The slow washout of 111In-RM2 from the
tumour is in contrast to that of 111In-bomproamide [21]
which showed as much as 70% loss within 4 h of injection.
111In-Bomproamide also shows faster washout from the
abdominal organs leading to similar tumour to background
ratios. Despite the fact that 111In-RM2 has an additional
positive charge and threefold greater Kd value than our
previously reported radioantagonist [22], we found little
improvement in regard to overall pharmacokinetics except
for a lower liver uptake leading to a significantly higher
tumour to liver ratio.
The excellent tumour to kidney and tumour to back-
ground ratios led us to study this analogue as a PET
imaging tool. We tested it in two animal models and with
two different cell lines. The peptide was labelled with 68Ga
and studied in PC-3 and LNCaP tumour-bearing male nude
mice. The PC-3 cell line is more representative of
androgen-independent tumour cells while the LNCaP cell
line is, currently, the closest representation of a human
prostatic carcinoma in cell culture [37, 38]. The pharmaco-
baba
ba
Tumor Tumor
Fig. 6 MicroPET/CT images of
LNCaP (a) and PC-3 (b)
tumour-bearing nude mice
after injection of 68Ga-RM2 at
1 h (a) and 1 h blocking (b)
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kinetics of 68Ga-RM2 in PC-3 tumours reflect what we
observed with 111In-RM2. Uptake in the tumour, in the
target tissues and in the kidney was high at early time
points but it decreased rapidly in all organs except the
tumour. The biodistribution data of the LNCaP tumour-
bearing nude mice showed similar pharmacokinetics but
with lower tumour uptake. The lower tumour uptake is in
line with the significant difference in the number of binding
sites of the two cell lines [34]. In all cases the high tumour
uptake and the high tumour to kidney ratio of 68Ga-RM2
are well visualized in the PET/CT images of the PC-3 and
LNCaP tumour-bearing nude mice. The ability of this
conjugate, and more generally, of many antagonists already
studied, to reach and maintain high tumour accumulation
despite the low internalization may be due to strong
receptor–antagonist interactions that produce a stable
complex [39].
111/natIn-RM2 behaved as an antagonist in several types
of in vitro internalization experiments, showing a very poor
receptor-mediated internalization in contrast to high surface
binding. It prevented bombesin-induced receptor internali-
zation in the immunofluorescence-based internalization
experiment. The high and specific tumour uptake and the
good tumour to background ratio at each time point indicate
that this analogue is a good candidate for diagnostic
purposes (PET/CT, SPECT/CT) and is potentially a good
candidate for human studies.
Acknowledgments We thank Prof. Marion de Jong and Dr. Cristina
Müller for support with the SPECT/CT measurements, Novartis
Pharma for analytical assistance, M.L. Tamma and S. Tschumi for
their expert technical help, and Bayer Schering Pharma for financial
support.
Conflict of interest Rosalba Mansi, Xuejuan Wang, Flavio Forrer,
Beatrice Waser, Renzo Cescato, Jean Claude Reubi and Helmut R.
Maecke declare that they have no conflict of interest.
References
1. Reubi JC, Macke HR, Krenning EP. Candidates for peptide
receptor radiotherapy today and in the future. J Nucl Med 2005;46
Suppl 1:67S–75S.
2. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor
targeting for tumor localisation and therapy with radiopeptides.
Curr Med Chem 2000;7:971–94.
3. Eisenwiener K-P, Prata MIM, Buschmann I, Zhang H-W, Santos AC,
Wenger S, et al. NODAGATOC, a new chelator-coupled somato-
statin analogue labeled with [67/68Ga] and [111In] for SPECT, PET,
and targeted therapeutic applications of somatostatin receptor
(hsst2) expressing tumors. Bioconjug Chem 2002;13:530–41.
4. Bodei L, Paganelli G, Mariani G. Receptor radionuclide therapy
of tumors: a road from basic research to clinical applications. J
Nucl Med 2006;47:375–7.
5. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly
efficient in vivo agonist-induced internalization of sst2 receptors
in somatostatin target tissues. J Nucl Med 2009;50:936–41.
6. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al.
Radiolabeled somatostatin receptor antagonists are preferable to
agonists for in vivo peptide receptor targeting of tumors. Proc Natl
Acad Sci U S A 2006;103:16436–41.
7. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in
the human prostate: relation to neoplastic transformation. Cancer
Res 1999;59:1152–9.
8. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of
receptors for bombesin/gastrin-releasing peptide and mRNA for
three receptor subtypes in human prostate cancers. Prostate
2000;42:295–303.
9. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-
neoplastic and neoplastic human breast. Am J Pathol
1999;155:2067–76.
10. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/
gastrin-releasing peptide receptors in human breast cancer and
their relationship to steroid receptor expression. Cancer Res
1995;55:280–7.
11. Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L. High
expression of peptide receptors as a novel target in gastrointestinal
stromal tumours. Eur J Nucl Med Mol Imaging 2004;31:803–10.
12. Toi-Scott M, Jones CL, Kane MA. Clinical correlates of
bombesin-like peptide receptor subtype expression in human lung
cancer cells. Lung Cancer 1996;15:341–54.
13. Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W,
Cocquyt V, Serreyn R, et al. Technetium-99m RP527, a GRP
analogue for visualisation of GRP receptor-expressing malignan-
cies: a feasibility study. Eur J Nucl Med 2000;27:1694–9.
14. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, et al.
Synthesis and evaluation of bombesin derivatives on the basis of
pan-bombesin peptides labeled with indium-111, lutetium-177,
and yttrium-90 for targeting bombesin receptor-expressing tumors.
Cancer Res 2004;64:6707–15.
15. Lantry LE, Cappelletti E, MaddalenaME, Fox JS, FengW, Chen J, et
al. 177Lu-AMBA: Synthesis and characterization of a selective
177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate
cancer. J Nucl Med 2006;47:1144–52.
16. Nock BA, Nikolopoulou A, Galanis A, Cordopatis P, Waser B,
Reubi JC, et al. Potent bombesin-like peptides for GRP-receptor
targeting of tumors with 99mTc: a preclinical study. J Med Chem
2005;48:100–10.
17. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J,
Fischler A, et al. Bombesin-like peptides can function as autocrine
growth factors in human small-cell lung cancer. Nature
1985;316:823–6.
18. Jensen RT, Coy DH. Progress in the development of potent bombesin
receptor antagonists. Trends Pharmacol Sci 1991;12:13–9.
19. Llinares M, Devin C, Chaloin O, Azay J, Noel-Artis AM, Bernad
N, et al. Syntheses and biological activities of potent bombesin
receptor antagonists. J Pept Res 1999;53:275–83.
20. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D,
Piccand V, et al. Bombesin receptor antagonists may be preferable
to agonists for tumor targeting. J Nucl Med 2008;49:318–26.
21. Abd-Elgaliel WR, Gallazzi F, Garrison JC, Rold TL, Sieckman
GL, Figueroa SD, et al. Design, synthesis, and biological
evaluation of an antagonist-bombesin analogue as targeting
vector. Bioconjug Chem 2008;19:2040–8.
22. Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, Waser B, et
al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-
acetic acid-conjugated bombesin-based radioantagonist for the
labeling with single-photon emission computed tomography,
positron emission tomography, and therapeutic radionuclides.
Clin Cancer Res 2009;15:5240–9.
23. Heppeler A, Froidevaux S, Mäcke H, Jermann E, Béhé M, Powell P,
et al. Radiometal-labelled macrocyclic chelator-derivatised somato-
statin analogue with superb tumour-targeting properties and potential
106 Eur J Nucl Med Mol Imaging (2011) 38:97–107
for receptor-mediated internal radiotherapy. Chem Eur J
1999;5:1974–81.
24. Azay J, Nagain C, Llinares M, Devin C, Fehrentz JA, Bernad N,
et al. Comparative study of in vitro and in vivo activities of
bombesin pseudopeptide analogs modified on the C-terminal
dipeptide fragment. Peptides 1998;19:57–63.
25. Coy DH, Mungan Z, Rossowski WJ, Cheng BL, Lin JT,
Mrozinski JE Jr, et al. Development of a potent bombesin receptor
antagonist with prolonged in vivo inhibitory activity on
bombesin-stimulated amylase and protein release in the rat.
Peptides 1992;13:775–81.
26. Atherton E, Sheppard R. Fluorenylmethoxycarbonyl-polyamide
solid phase peptide synthesis. General principles and develop-
ment. Oxford: Oxford Information Press; 1989.
27. Velikyan I, Beyer GJ, Langstrom B. Microwave-supported
preparation of (68)Ga bioconjugates with high specific radioac-
tivity. Bioconjug Chem 2004;15:554–60.
28. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M.
Bombesin receptor subtypes in human cancers: detection with the
universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13),
NLE(14)] bombesin(6-14). Clin Cancer Res 2002;8:1139–46.
29. Vigna SR, Mantyh CR, Giraud AS, Soll AH, Walsh JH, Mantyh
PW. Localization of specific binding sites for bombesin in the
canine gastrointestinal tract. Gastroenterology 1987;93:1287–95.
30. Fleischmann A, Laderach U, Friess H, Buechler MW, Reubi JC.
Bombesin receptors in distinct tissue compartments of human
pancreatic diseases. Lab Invest 2000;80:1807–17.
31. Forrer F, Valkema R, Bernard B, Schramm NU, Hoppin JW,
Rolleman E, et al. In vivo radionuclide uptake quantification using
a multi-pinhole SPECT system to predict renal function in small
animals. Eur J Nucl Med Mol Imaging 2006;33:1214–7.
32. Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J,
Sharp TL, et al. MicroPET imaging of a gastrin-releasing peptide
receptor-positive tumor in a mouse model of human prostate
cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem
2003;14:756–63.
33. Maddalena ME, Fox J, Chen J, Feng W, Cagnolini A, Linder KE,
et al. 177Lu-AMBA biodistribution, radiotherapeutic efficacy,
imaging, and autoradiography in prostate cancer models with
low GRP-R expression. J Nucl Med 2009;50:2017–24.
34. Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J. Bombesin
specifically induces intracellular calcium mobilization via gastrin-
releasing peptide receptors in human prostate cancer cells. J Mol
Endocrinol 1996;16:297–306.
35. Wadas TJ, Eiblmaier M, Zheleznyak A, Sherman CD, Ferdani
R, Liang K, et al. Preparation and biological evaluation of
64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET
imaging of somatostatin receptor-positive tumors. J Nucl Med
2008;49:1819–27.
36. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides
in tumor imaging. J Nucl Med 2005;46 Suppl 1:172S–8S.
37. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E,
Sullivan LD. A metastatic and androgen-sensitive human prostate
cancer model using intraprostatic inoculation of LNCaP cells in
SCID mice. Cancer Res 1997;57:1584–9.
38. Jantscheff P, Ziroli V, Esser N, Graeser R, Kluth J, Sukolinskaya
A, et al. Anti-metastatic effects of liposomal gemcitabine in a
human orthotopic LNCaP prostate cancer xenograft model. Clin
Exp Metastasis 2009;26:981–92.
39. Vauquelin G, Van Liefde I, Birzbier BB, Vanderheyden PM. New
insights in insurmountable antagonism. Fundam Clin Pharmacol
2002;16:263–72.
Eur J Nucl Med Mol Imaging (2011) 38:97–107 107
